Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

BACKGROUND: Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC). Everolimus acts synergistically with eribulin in TNBC cell lines and xenograft models. This phase I trial was designed to test the safety and tolerability of combinin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Lee, Jin Sun, Yost, Susan E., Blanchard, Suzette, Schmolze, Daniel, Yin, Hongwei Holly, Pillai, Raju, Robinson, Kim, Tang, Aileen, Martinez, Norma, Portnow, Jana, Wen, Wei, Yim, John H., Brauer, Heather Ann, Ren, Yuqi, Luu, Thehang, Mortimer, Joanne, Yuan, Yuan
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6839083/
https://ncbi.nlm.nih.gov/pubmed/31703728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-019-1202-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados